T-Cell LymphomaSymptoms, Doctors, Treatments, Advances & More
T-Cell Lymphoma Overview
Learn About T-Cell Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Christiane Querfeld, M.D., PH.D.
Christiane Querfeld is a Dermatologist practicing medicine in Duarte, California. Dr. Querfeld is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. She is also highly rated in 20 other conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, and Sezary Syndrome. Dr. Querfeld is currently accepting new patients.
Stanford University
Youn-hee Kim is a Dermatologist practicing medicine in Palo Alto, California. Dr. Kim is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Sezary Syndrome. Dr. Kim is currently accepting new patients.
UVA Health Emily Couric Clinical Cancer Center
Enrica Marchi is a Hematologist practicing medicine in Charlottesville, Virginia. Dr. Marchi is rated as an Elite provider by MediFind in the treatment of T-Cell Lymphoma. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Bone Marrow Aspiration. Dr. Marchi is currently accepting new patients.
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes. This can lead to an enlarged spleen and lymph nodes. Current treatments for ALPS can have many adverse effects. Better treatments for ALPS are needed.
Summary: Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (...